Mark Bakken
Founder, Managing Director @ HealthX Ventures
Madison, United States
Mark Bakken is a seed investor at HealthX Ventures in Madison focused on Health Care and Information Technology. Mark Bakken is the Founder and Managing Director of HealthX Ventures. He is also a General Partner at Cultivation Capital. He previously worked at Nordic as a Co-Founder and CEO. Mark Bakken attended the University of Wisconsin-Madison.
- Total investments:
- 25
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Mark Bakken invests in
Stages Mark Bakken invests in
Countries Mark Bakken invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $300k–$4M
- Series A
- $2M–$27M
Investment Focus
Industry
- Health Care 13 (52%)
- Information Technology 6 (24%)
- Software 5 (20%)
- Medical 4 (16%)
- Hospital 3 (12%)
Stage
- Seed 12 (48%)
- Series A 6 (24%)
- Venture - Series Unknown 2 (8%)
- Pre-Seed 1 (4%)
- Series B 1 (4%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| KeyCare is a virtual care platform powered by Epic that was created to assist forward-thinking health systems in increasing patient access and quality by enhancing the alternatives available for virtual care. | $27.4M / Series A / Mar 03, 2026 | ||
| Cylerity's fintech platform inserts between the clearinghouse and the payor, avoiding the need for providers to make changes to their operations or RCM procedures. The advance is made within hours of submitting the claim, allowing saving programs to be implemented from procurement to debt service. With cylerity, commercial insurance claims andmedicare reimbursements can be processed rapidly. | $4M / Seed / Oct 28, 2025 | ||
| WPS, a health solutions company, is an independent, not-for-profit, local partner based in Madison, Wisconsin. We’ve provided health insurance and benefit plan administration to millions of private and government members for almost 80 years. To us, it’s about more than delivering trusted and unparalleled expertise in the most demanding ofbusinesses. It’s also about caring for those we serve—and exploring new and innovative ways to bring value to their lives. | Venture - Series Unknown / Oct 20, 2025 | ||
| Brooklyn Health is a company of clinicians, scientists, and engineers dedicated to enhancing digital health measurement. | $6.5M / Seed / May 27, 2025 | ||
| Amulet is shining a light on invisible threats in our food system. Amulet has two core brands: - Allergy Amulet helps consumers determine whether their foods are safe by detecting potentially life-threatening allergenic ingredients. - Amulet Scientific equips businesses and manufacturers with tools to help ensure the safety of their food supplychain. Learn more: www.allergyamulet.com www.amuletscientific.com | $5.8M / Series A / Aug 12, 2024 | ||
| Allergy Amulet is the world’s smallest and fastest consumer food allergen sensor, testing for common allergenic ingredients in seconds. Whether it’s on a keychain, a necklace, a wristband, or in a pocket, Allergy Amulet’s sleek and portable design allows users to savor life’s important moments, safely and simply. Food allergies affect 32 millionAmericans and between 220-520 million people globally. That’s 1 in 13 children and 1 in 10 adults. Allergy Amulet has the potential to improve the quality of life for the millions of people living with food allergies or intolerances. | $5.8M / Series A / Aug 12, 2024 | ||
| RxLightning is a digital solution for specialty medication access, accelerating patients’ speed to therapy. | $17.5M / Series A / Jun 06, 2023 | ||
| CancerIQ provides a precision prevention platform that empowers healthcare providers to engage patients, stratify risk and ensure adherence with the latest evidence-based strategies to get ahead of cancer. It offers a robust content library of evidence-based guidelines and risk models to help providers interpret data and navigate patients to theappropriate genetic testing, screening, or treatment interventions. | $14M / Series B / Mar 03, 2022 | ||
| Ideawake provides an easy to use innovation platform combined with programs, services, and expertise that supports the innovation program. Its SaaS idea management platform enables employers to (1) solicit and crowdsource ideas of employees, customers, and vendors to reduce costs, generate additional revenue and engage employees, (2) evaluate andselect the best ideas, and (3) manage the implementation of those ideas. It aims to empower brands with the tools, processes, and connections they need to transform employees into innovators and their ideas into measurable impact.Ideawake was founded in 2013 and is headquartered in Milwaukee, Wisconsin. | $1M / Seed / Feb 03, 2022 | ||
| Nurse Disrupted solves complex health problems through simple solutions. | $700K / Seed / Nov 24, 2021 | ||
| See all 25 investments → | |||
Co-Investors
About HealthX Ventures
HealthX Ventures is a digital healthcare-focused venture capital firm. They invest in innovative companies making healthcare safer, more efficient, and more affordable by delivering easy-to-use, cost-effective, and scalable solutions to the market.
HealthX Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alexis Johnson
Executive Assistant / Office Manager
|
|||
Brian Lindstrom
Operating Partner
|
|||
|
Joel Martin
Partner
|
|||
Kristi Ebong
Partner
|
|||
|
Mark Bakken
Founder, Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Mark Bakken invest in?
Mark Bakken invests primarily in Health Care, Information Technology and Software startups, most often at Seed and Series A stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Mark Bakken invest in?
Mark Bakken typically joins rounds of $300k–$4M at Seed and $2M–$27M at Series A. These are whole funding-round sizes, not Mark Bakken's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Mark Bakken took part in.
How do I contact Mark Bakken?
Public channels for Mark Bakken include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Mark Bakken last invest?
The most recent investment recorded for Mark Bakken closed in Mar 2026. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
